Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Xcel Energy Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $510.72 (market cap $127.55B), while Xcel Energy Inc trades at $73.45 (market cap $45.82B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.8× Xcel Energy Inc's market cap, and Xcel Energy Inc pays a 3.23% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Xcel Energy Inc for 61 Days on average.
| VRTX | XEL | |
|---|---|---|
Market Cap | $127.55B | $45.82B |
Volume | 1,487,944 | 6,910,516 |
Sector | Health | Utilities |
52-Week High | $557.96 | $83.91 |
52-Week Low | $407.37 | $69.39 |
Typical Hold Time | 120 Days | 61 Days |
Enterprise Value | $121.68B | $84.14B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Xcel Energy (XEL) trades at $72.42, down 0.43% with a bearish technical signal despite recent earnings beats. The stock shows solid fundamentals with $14.67B revenue, 15.28% net margin, and consistent cash flow growth. Analyst consensus is bullish with a $90.83 price target (62.96% buy rating), while institutional activity shows mixed positioning. Recent news highlights data center power demand growth and wildfire liability concerns.
XEL offers attractive utility exposure with 11% rate base growth potential and dividend stability, but faces regulatory and wildfire litigation risks. The current valuation at 20.1x P/E appears reasonable given earnings trajectory, though technical weakness near support at $71-72 requires monitoring for entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
